Mainz Biomed (QUCY) Stock Price, News & Analysis

Company Overview

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Key Stats

• Today's Range: $0.35 to $0.40
• 50-Day Range: N/A
• 52-Week Range: $0.35 to $2.84
• Volume: 522,531 shs
• Average Volume: 1.40 million shs
• Market Capitalization: $4.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Mainz Biomed Stock Analysis - MarketRank™

Mainz Biomed scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Mainz Biomed has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Mainz Biomed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mainz Biomed is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mainz Biomed is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mainz Biomed has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for QUCY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mainz Biomed does not currently pay a dividend.

Dividend Growth

Mainz Biomed does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mainz Biomed insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.80% of the stock of Mainz Biomed is held by insiders.

Percentage Held by Institutions

Mainz Biomed has minimal institutional ownership at this time.

QUCY Stock Analysis - Frequently Asked Questions

How have QUCY shares performed this year?

Mainz Biomed's stock was trading at $0.7374 at the beginning of 2026. Since then, QUCY shares have decreased by 50.6% and is now trading at $0.3640.

How were Mainz Biomed's earnings last quarter?

Mainz Biomed NV (NASDAQ:QUCY) posted its earnings results on Tuesday, March, 31st. The company reported ($0.03) EPS for the quarter. The business had revenue of $0.13 million for the quarter.

How do I buy shares of Mainz Biomed?

Shares of QUCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QUCY
• CIK: 1874252
• Web: N/A
• Phone: 49 6131 5542860
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.55
• Current Ratio: 0.50
• Quick Ratio: 0.44

Sales & Book Value

• Annual Sales: $540 thousand
• Price / Sales: 8.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 5.20

Miscellaneous

• Outstanding Shares: 12,520,000
• Free Float: 11,289,000
• Market Cap: $4.56 million
• Optionable: N/A
• Beta: 0.42